Audit: QRS - Magnesium for Health & Longevity
Audit conducted on 22/08/2026 11:12 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every span traces to ER text: protocol cells to Therapeutic Protocol, time-to-effect to Practical Considerations, benefit/risk tiers to the ER tier headings, gates to Key Interactions & Contraindications, markers and cadence to Monitoring Protocol & Defining Success. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | No ER section is empty and no cautious empty-state phrasing exists in the ER that the QRS needed to carry over. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications retain the avoid-level framing; “unless nephrologist-supervised” is equivalent to the ER’s “unless prescribed and monitored by a nephrologist”. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | All ten caution items come from the ER’s interaction bullets; all five stop items come from “Populations who should avoid Magnesium”. No modifying factor is surfaced as a gate or a risk. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS contains no PMIDs, citations, NCT identifiers, expert names or brand names at all. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind appear in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Phrasing is lifted or lightly condensed from the ER throughout, preserving its measured, non-promotional register. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Tiered benefits and risks, numeric targets and a concrete cadence carry the data-driven register without hype. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated as findings and targets, not as orders to a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No prescriptive verbs directed at a patient; the footer disclaimer is the template’s own text. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Values are declarative (“Split dosing preferred”, “Evening for glycinate and L-Threonate”); the cadence is a schedule, not an instruction. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the file (verified across the whole document). |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms appear only where they are the marker or condition name; the At-A-Glance span is fully plain-language. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Twelve ER protocol bullets condensed to three cells; benefit and risk tiers reduced to semicolon-separated headings with all magnitudes stripped. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no “you”/”your” in any span. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Functional-range targets (serum magnesium 0.85–0.95 mmol/L, HbA1c below 5.4%) and an eight-marker panel address an optimizing, self-testing reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Split dosing, evening timing by form, and repeat laboratory panels all assume willingness to accept inconvenience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Red-blood-cell magnesium, fasting insulin and 7-morning home blood pressure are not general-population expectations. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The At-A-Glance and time-to-effect cells foreground that the benefit concentrates in the depleted, hypertensive or medicated, matching the ER’s own weighting. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “Longevity” appears in the title and header topic; “anti-aging” appears nowhere. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Clinical register throughout (“Gastrointestinal adverse effects”, “hypermagnesemia”, “orthostatic”-level precision); the plainer wording in At-A-Glance is required by item 7.4 and is taken from the ER Conclusion. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed strings are byte-identical to [qrs_template] (lines 437, 474, 516, 553, 572, 603, 536, 542, tier <strong> labels, and the three <th> cells). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 20 unique single-instance variables present, plus marker_1–8 (name/target/why) and qualitative_item_1–6, and action_1–3 / time_1–3 label/value/sub. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A full diff of the QRS against [qrs_template] shows changes confined to metadata values and to checklist-addressed spans; style block, comments, website="…" spans and footer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section used by the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Total intake target”, “Single versus split doses” and “Best time of day” are verbatim ER bold labels (ER lines 388, 394, 390). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | The three protocol labels are verbatim; time-to-effect labels are drawn from the ER’s own time-to-effect wording. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji code points anywhere in the file; the ER’s tier and “⚠️ Conflicted” emoji were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every oversize source section was condensed rather than carried over: 12 protocol bullets → 3 cells, 4 time-to-effect statements → 3 cells, all magnitude paragraphs stripped, drug example lists trimmed. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14; it is the first element after the doctype on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | It sits entirely inside an HTML comment and no metadata value is repeated in the body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, and it contains a colon so quoting is required. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: magnesium_2026-0822-0916_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the version badge in QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0822-1058. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the on-disk filename magnesium_2026-0822-0916_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys including git_user and git_issue; no stray whitespace or quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: Magnesium for Health & Longevity - Quick Reference Sheet, matching ER canonical_topic with & encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: Magnesium for Health & Longevity. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 08/22/2026, correctly derived from 2026-0822-1058. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header div (lines 415–428) is structurally identical to the template; the ER’s “Also known as” line was correctly not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion (lines 500–504) into the intake gap, the three best-supported effects, and the harm profile. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 56 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Intake gap → ER line 500; the three best-supported effects → ER line 502; loose stools, form dependence and drug absorption → ER line 504; kidney-limited accumulation → ER line 504. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; uses “loose stools”, “blood-sugar handling”, “serious buildup”, “impaired kidneys”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year or sample size appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | “a small blood-pressure fall” carries no numbers, confidence intervals or risk ratios. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All five items map to the “Populations who should avoid Magnesium” list in that ER section (ER lines 356–360). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All five ER avoid-populations are present, none invented. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 576–586: five discrete <li> elements inside the span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | No dashes or trailing clauses; the ER’s plain-language glosses (“a stalled bowel”, “very slow stomach emptying”) were correctly stripped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | eGFR below 30 mL/min/1.73 m², the nephrologist-supervision exception, “second- or third-degree”, the bradycardia indication, and “untreated or unstable” are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names five such populations and the section is correctly populated rather than left empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All ten items map one-to-one to the ER’s ten interaction bullets (ER lines 334–352). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All ten interaction bullets present; no overlap with the five contraindication items. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 594–618: ten discrete <li> elements inside the span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s Caution/Monitor tags and mechanistic sentences are all stripped; no dash-trailing clauses remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Drug examples retained for every bullet that had them (trimmed, e.g. esomeprazole and minocycline dropped, never emptied), plus the 2 h / 4–6 h and 4 h windows and the 142 mg/day zinc threshold. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names ten interactions and the section is correctly populated rather than left empty. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from the ER Therapeutic Protocol section (ER lines 388, 390, 394). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Total intake target, single versus split dosing, and timing by form are the three universally applicable actions; the three expert-attributed approach bullets are correctly excluded under item 1.5. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section contains twelve actionable bullets, well above three. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans (lines 450–487) carry ER-derived content; no placeholders remain. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Tissue repletion, blood pressure and sleep/migraine, all from the ER “Time to effect” bullet (ER line 436); the fourth item, bowel effects, is folded into time_3_sub. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Tissue repletion (High: Correction of Inadequate Magnesium Status) → blood pressure (High: Blood Pressure Reduction) → sleep and migraine (Medium/Low), matching the ER’s own benefit ordering. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER names four distinct time-to-effect aspects. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans (lines 498–531) are populated; time_1_sub draws on the ER Half-life bullet, time_2_sub on the ER blood-pressure benefit paragraph. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides an explicit “Time to effect” bullet. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All sixteen listed benefits are ER Expected Benefits sub-headings. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present (lines 541, 547, 554, 561) with tier assignments matching the ER exactly: 3 High, 4 Medium, 7 Low, 2 Speculative. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the bare ER sub-heading; every Magnitude line, confidence interval and citation was dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any of the four benefit spans. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers contain items in the ER. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All seven listed risks are ER Potential Risks & Side Effects sub-headings. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present (lines 630, 633, 639, 645) with tier assignments matching the ER exactly: 1 High, 2 Medium, 2 Low, 2 Speculative. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the bare ER sub-heading; the relative risks, dose thresholds and case-report detail were all dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any of the four risk spans. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers contain items in the ER. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | All eight rows come from the ER Monitoring Protocol & Defining Success biomarker table (ER lines 466–473). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER biomarkers present: serum magnesium, red-blood-cell magnesium, eGFR and creatinine, serum potassium and calcium, HbA1c and fasting insulin, 25-hydroxyvitamin D, hs-CRP, home blood pressure. Targets and “why” text match the ER’s Optimal Functional Range and Why Measure It? columns. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 784–788 reproduce the ER cadence paragraph (ER lines 460, 462): baseline, 2 weeks and 3 months, 3 months, annual, and 6-monthly for reduced filtration or above 350 mg/day. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items come from the “Qualitative markers worth tracking” list in the ER Monitoring Protocol & Defining Success section (ER lines 477–482). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six are present and verbatim: sleep onset and night waking, headache frequency/duration/severity, muscle twitching and cramps, bowel pattern, anxiety and stress reactivity, daytime energy and recovery. |
Issues 22/08/2026 11:12
Pass rate 100.00%. No issues found.
Issues 22/08/2026 11:05
- 12.3 / 12.4 — “(conflicted)” qualifier retained in benefits: [benefits_low] keeps the parenthetical evidence-strength qualifier “(conflicted)” on “improved arterial stiffness and endothelial function” and “reduced inflammatory markers” (QRS lines 556–559), although Section 12 requires all qualifiers and parenthetical content to be stripped because the tier already encodes evidence strength.
Fixes 22/08/2026 11:05
- 12.3 / 12.4 — “(conflicted)” qualifier removed: Stripped both “(conflicted)” parentheticals from [benefits_low], leaving “improved arterial stiffness and endothelial function; reduced inflammatory markers” so the tier alone carries the evidence-strength signal.